(Q58029880)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Paolo Milani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Francesca Lavatelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Mario Nuvolone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Laura Obici

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Stefano Perlini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Giampaolo Merlini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

A Foli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

M Vidus Rosin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

M Basset

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

25 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

2311-2316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.227

10 March 2020

exact match

0 references

cites work

Dangerous small B-cell clones.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Light chain amyloidosis: the heart of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Systemic light chain amyloidosis: an update for treating physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

How to manage primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Introducing the new editor of amyloid: the journal of protein folding disorders, Per Westermark, M.D., Ph.D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Transplantation vs. conventional-dose therapy for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Update on treatment of light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.227

Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts

21 January 2018

1 reference

12 December 2020

Holter monitoring in AL amyloidosis: prognostic implications

1 reference

12 December 2020

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

12 December 2020

Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis.

1 reference

12 December 2020

Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1

1 reference

12 December 2020

Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25059496%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference